Boehringer Ingelheim Reports Real-World Data for Spiriva Respimat (tiotropium bromide) Inhalation Spray 1.25mcg in Patients with Asthma
Boehringer’s Ofev (nintedanib) Receives FDA’s Advisory Committee Recommendation for Systemic Sclerosis Associated ILD
Shots:
- The real-world data involves assessing of Spiriva Respima Inhalation Spray 1.25mcg + combination inhaled corticosteroid and long-acting beta2-agonist (ICS+LABA) vs increased dose of ICS+LABA or continuing high dose of ICS+LABA in patients with asthma
- The study resulted in 73% lower exacerbation rates and 76% lower hospitalization rates in comparison to increased dose of ICS+LABA for 12 months
- Spiriva Respimat (tiotropium bromide) is a 1.25mcg long term once-daily maintenance treatment of asthma for 6 years and older
Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Twitter